mTNBC
Oncology · 2021–2021
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| atezolizumab First-line treatment of metastatic triple-negative breast cancer (mTNBC) in combination with nab-paclitaxel in patients with PD-L1-positive tumours (≥1% PD-L1… | Mar 2021 | Not recommended | 1 individuals Breast Cancer Network Australia · Medical Oncology Group |
Who spoke
Breast Cancer Network Australia · Medical Oncology Group
What the PBS pays
$157M in government benefit over 2024–25, across 21,646 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| atezolizumab | $156.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.